JD Supra

FCA sets aside PMPRB’s order that Galderma’s patent claiming 0.3% adapalene “pertained to” 0.1% adapalene DIFFERIN

On December 3, 2024, the Federal Court of Appeal (FCA) set aside the order of the Patented Medicine Prices Review Board (PMPRB or Board) that had required Galderma to continue to provide information ...
JD Supra

Federal Court finds PMPRB reasonably concluded Galderma’s patent claiming 0.3% adapalene “pertained to” 0.1% adapalene DIFFERIN

Galderma markets two adapalene cream products: DIFFERIN (0.1% adapalene) and DIFFERIN XP (0.3% adapalene). In 2016, PMPRB staff alleged that Galderma had failed to provide information regarding ...